Mercy BioAnalytics Receives FDA Approval to Initiate Prospective Pivotal Study of Evident™Ovarian Cancer Screening Test

RegulatoryapprovedEvident™Positive

AI Analysis

Summary

Mercy BioAnalytics received FDA IDE approval to initiate the SOARA pivotal clinical validation study for its Evident™ ovarian cancer screening test in average-risk women. This regulatory milestone enables the company to proceed with prospective testing following IRB approval.

Clinical Trial Data

Phase

pivotal

Outcome Details

FDA IDE approval to initiate prospective pivotal study

Importance:7/10

Sentiment:

0.75

FDA approvalIDEovarian cancerscreeningclinical trialregulatory

Read the original article

Published by PR Newswire Biotech on September 21, 2026 5:27 PM

Read Original